Recent Advancements in MRNA Vaccines: From Target Selection to Delivery Systems

Overview

Journal Vaccines (Basel)

Date 2024 Aug 29

PMID 39203999

Authors

Zhongyan Wu

Weilu Sun

Hailong Qi

Affiliations

Soon will be listed here.

Abstract

mRNA vaccines are leading a medical revolution. mRNA technologies utilize the host's own cells as bio-factories to produce proteins that serve as antigens. This revolutionary approach circumvents the complicated processes involved in traditional vaccine production and empowers vaccines with the ability to respond to emerging or mutated infectious diseases rapidly. Additionally, the robust cellular immune response elicited by mRNA vaccines has shown significant promise in cancer treatment. However, the inherent instability of mRNA and the complexity of tumor immunity have limited its broader application. Although the emergence of pseudouridine and ionizable cationic lipid nanoparticles (LNPs) made the clinical application of mRNA possible, there remains substantial potential for further improvement of the immunogenicity of delivered antigens and preventive or therapeutic effects of mRNA technology. Here, we review the latest advancements in mRNA vaccines, including but not limited to target selection and delivery systems. This review offers a multifaceted perspective on this rapidly evolving field.

Citing Articles

Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong K, Tham S, Poh C Virol J. 2025; 22(1):71.

PMID: 40075519 PMC: 11900334. DOI: 10.1186/s12985-025-02645-6.

Animal Trypanosomiasis: Challenges and Prospects for New Vaccination Strategies.

Pereira S, Alves F, Teixeira S Microorganisms. 2025; 12(12.

PMID: 39770779 PMC: 11678697. DOI: 10.3390/microorganisms12122575.

mRNA vaccines as cancer therapies.

Huang S, Que H, Wang M, Wei X Chin Med J (Engl). 2024; 137(24):2979-2995.

PMID: 39668413 PMC: 11706586. DOI: 10.1097/CM9.0000000000003455.

Recent Advances and Prospects in RNA Drug Development.

Tani H Int J Mol Sci. 2024; 25(22).

PMID: 39596348 PMC: 11594839. DOI: 10.3390/ijms252212284.

References

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N . Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2021; 601(7893):410-414. PMC: 8770133. DOI: 10.1038/s41586-021-04231-6. View

Fan N, Chen K, Zhu R, Zhang Z, Huang H, Qin S . Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants. Sci Adv. 2022; 8(51):eabq3500. PMC: 9788765. DOI: 10.1126/sciadv.abq3500. View

Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z . Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022; 13(1):5561. PMC: 9508184. DOI: 10.1038/s41467-022-33157-4. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

Bahr-Mahmud H, Ellinghaus U, Stadler C, Fischer L, Lindemann C, Chaturvedi A . Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody. Oncoimmunology. 2023; 12(1):2255041. PMC: 10583639. DOI: 10.1080/2162402X.2023.2255041. View

Wang J, Wang Q, Ma L, Lv K, Han L, Chen Y . Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies. Mol Ther. 2024; 32(7):2340-2356. PMC: 11286823. DOI: 10.1016/j.ymthe.2024.04.036. View

Fang Z, Monteiro V, Renauer P, Shang X, Suzuki K, Ling X . Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 2023; 33(5):407-410. PMC: 9988199. DOI: 10.1038/s41422-023-00792-5. View

Grudzien-Nogalska E, Stepinski J, Jemielity J, Zuberek J, Stolarski R, Rhoads R . Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. Methods Enzymol. 2007; 431:203-27. DOI: 10.1016/S0076-6879(07)31011-2. View

10.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

11.

Bicknell A, Reid D, Licata M, Jones A, Cheng Y, Li M . Attenuating ribosome load improves protein output from mRNA by limiting translation-dependent mRNA decay. Cell Rep. 2024; 43(4):114098. DOI: 10.1016/j.celrep.2024.114098. View

12.

Fan M, Lai F, Cheng F, Tsie N, Li X, Wan E . Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case-control study. Lancet Reg Health West Pac. 2023; 35:100745. PMC: 10039395. DOI: 10.1016/j.lanwpc.2023.100745. View

13.

Ma Y, Fenton O . A Unified Strategy to Improve Lipid Nanoparticle Mediated mRNA Delivery Using Adenosine Triphosphate. J Am Chem Soc. 2023; 145(36):19800-19811. DOI: 10.1021/jacs.3c05574. View

14.

Packer M, Gyawali D, Yerabolu R, Schariter J, White P . A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun. 2021; 12(1):6777. PMC: 8608879. DOI: 10.1038/s41467-021-26926-0. View

15.

Tahtinen S, Tong A, Himmels P, Oh J, Paler-Martinez A, Kim L . IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022; 23(4):532-542. DOI: 10.1038/s41590-022-01160-y. View

16.

Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K . Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023; 14(1):2657. PMC: 10175277. DOI: 10.1038/s41467-023-38244-8. View

17.

Hewitt S, Bailey D, Zielinski J, Apte A, Musenge F, Karp R . Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020; 26(23):6284-6298. DOI: 10.1158/1078-0432.CCR-20-0472. View

18.

McBride A . Human papillomaviruses: diversity, infection and host interactions. Nat Rev Microbiol. 2021; 20(2):95-108. DOI: 10.1038/s41579-021-00617-5. View

19.

Passmore L, Coller J . Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2021; 23(2):93-106. PMC: 7614307. DOI: 10.1038/s41580-021-00417-y. View

20.

Wilson E, Goswami J, Baqui A, Doreski P, Perez-Marc G, Zaman K . Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023; 389(24):2233-2244. DOI: 10.1056/NEJMoa2307079. View